Please login to the form below

Not currently logged in

PMEA Company of the Year (<£150m)



Summary of work

Otsuka has taken deliberate steps to forge a different path to its contemporaries and peers. The company’s goal is to develop unique, innovative, first-in-class products, focusing on unmet medical needs and the needs of customers. This is where it has the edge – without a cumbersome infrastructure and empowered by our financial success in Japan and the US, it has been able to build a responsive network of talented people to address these needs.

In more than 30 years of pharmaceutical research in Europe, Otsuka has remained at the forefront of scientific advances. Otsuka Europe is committed to developing world-class treatments that improve the health of people in Europe and focuses its research and development efforts on identifying and addressing unmet medical needs particularly in the specialist areas of cardiovascular, gastrointestinal and central nervous system disorders.  

Otsuka currently has several compounds at various stages of clinical development around the world. Based in Germany since 1982, the Otsuka Frankfurt Research Institute (OFRI) is focused on clinical development, conducting research in Phases I, II, III and IV and providing regulatory and pharmacovigilence services to the European business.

Judges comments

"A very effective company with a strong leadership team, which is always challenging itself to do better. Otsuka has a highly committed sales approach, tailored to specific customers. Definitely one to watch."

Key dates

Entry deadline 29 August 2019
Extended entry deadline 5 September 2019*
*additional fee applies
Judging day 26 September 2019
Company/Team Interviews 9 October 2019
PMEA Event 27 November 2019